![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TRANSTECH PHARMA, INC. ANNOUNCES ACHIEVEMENT OF A MILESTONE BY NOVO NORDISK
TRANSTECH PHARMA, INC. ANNOUNCES ACHIEVEMENT OF A MILESTONE BY NOVO NORDISK
September 23, 2005
TransTech Pharma, Inc. (TransTech) today announced it had received a milestone payment from its collaboration partner, Novo Nordisk, as a result of progress made with a drug candidate resulting from their collaboration. This milestone was in addition to another development milestone that TransTech previously reported in October 2004. The compound was discovered during a strategic research collaboration between the two companies utilizing TransTech's proprietary small molecule discovery engine TTP Translational Technology(R).
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050922005140&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct